In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

In September, the company officially relocated its headquarters from a 114,000-square-foot space in New York City to a ...

Abcellera Biologics, Inc. ( (ABCL) ) has released its Q3 earnings. Here is a breakdown of the information Abcellera Biologics, Inc. presented ...

Despite a widened net loss, AbCellera Biologics Inc (ABCL) strengthens its pipeline and partnerships, maintaining robust ...

Year-over-year BioSpace data shows there are fewer job postings live on the website and far more competition for them.

Good afternoon, and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia, and I will facilitate ...

AbCellera Forward-looking Statements. This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Secur ...

Good afternoon and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia and I will facilitate the audio portion of today's interactive broadcast. (Operator Instructions).

Operator: Good afternoon, and welcome to AbCellera’s Q3 2024 Business Update Conference Call. My name is Tamiya, and I will ...

Obesity has been a big topic recently, with Novo Nordisk and Eli Lilly leading the way with their GLP-1 agonists Wegovy and ...

Conditions are getting a bit more challenging for the drugmaker.

Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...